Certara, Inc. (NASDAQ:CERT – Get Free Report) has earned a consensus recommendation of “Hold” from the thirteen brokerages that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $8.85.
CERT has been the subject of a number of recent research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Certara in a research report on Friday, May 29th. Stephens reduced their target price on shares of Certara from $10.00 to $9.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Craig Hallum reduced their target price on shares of Certara from $10.00 to $8.00 and set a “hold” rating for the company in a research report on Tuesday, May 12th. BMO Capital Markets reduced their target price on shares of Certara from $7.00 to $6.00 and set a “market perform” rating for the company in a research report on Tuesday, May 12th. Finally, Morgan Stanley reduced their target price on shares of Certara from $11.00 to $10.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th.
View Our Latest Stock Report on CERT
Institutional Investors Weigh In On Certara
Certara Trading Up 16.1%
Shares of NASDAQ:CERT opened at $6.05 on Wednesday. Certara has a 12-month low of $4.45 and a 12-month high of $13.88. The stock has a market cap of $941.20 million, a PE ratio of -60.50 and a beta of 1.49. The business has a 50 day moving average of $5.59 and a 200-day moving average of $7.12. The company has a quick ratio of 1.88, a current ratio of 1.88 and a debt-to-equity ratio of 0.28.
Certara (NASDAQ:CERT – Get Free Report) last issued its quarterly earnings data on Monday, May 11th. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.The firm had revenue of $106.92 million for the quarter, compared to the consensus estimate of $106.13 million. During the same quarter in the prior year, the firm earned $0.14 EPS. The company’s revenue was up .8% on a year-over-year basis. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. As a group, equities research analysts forecast that Certara will post 0.24 earnings per share for the current year.
About Certara
Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.
The company’s offerings are divided into software tools and consulting services.
Read More
- Five stocks we like better than Certara
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
- 3 Rate-Ready Stocks for the New Fed Chair’s First Big Test
Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.
